Pharma companies see pricing concessions as the lesser of two evils, as the price cuts grant exemption from Trump’s tariffs on US drug imports.

The Trump administration announced lower Medicare prices for 15 prescription drugs via the Medicare drug price negotiation program. The new prices will take effect starting January 1, 2027. The biggest hit will fall on pharma companies with drugs selected in both rounds of Medicare negotiations. Revenue impacts will vary depending on each product’s time on the market and how far the negotiated price falls below prior net sales after rebates and discounts. For the government, savings on these drugs will be significant, but broader program savings won’t materialize until far more than 25 drugs see price cuts.

British pharma company GSK plans to invest $30 billion in US drug manufacturing and R&D, coinciding with President Trump’s UK state visit and a broader pullback on UK investments by other drugmakers. Since taking office, Trump has issued executive orders and warnings aimed at spurring more US manufacturing and lowering drug prices. While his approach is boosting manufacturing, it doesn’t necessarily translate to lower drug prices. For increased US manufacturing to truly benefit consumers, it needs to be coupled with reforms in how drugs are priced, negotiated, and reimbursed. Without cooperation from the full supply chain—from pharma companies to providers, pharmacy benefit managers, insurers, and federal and state governments—manufacturing growth alone won’t guarantee lower prices for patients.

Declining revenue, data breaches, and user mistrust jeopardize its future, leaving its vast genetic data trove in limbo as the company struggles to pivot.

Sanofi in talks to sell 50% stake in Opella: The pharma company joins other drugmakers shedding their consumer health businesses to better focus on bolstering their prescription drug pipelines.